Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

S.C.P.C Investor Presentation 2021

Nov 17, 2021

51900_rns_2021-11-17_0511c666-53a8-4a4e-aae4-2726626e7969.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

生達化學製藥股份有限公司 Standard Chem & Pharm CO., LTD. 股票代號 1720 2021 法人說明會 2021 年 11 月 18 日

==> picture [508 x 268] intentionally omitted <==

==> picture [320 x 85] intentionally omitted <==

簡報概要

==> picture [98 x 91] intentionally omitted <==

生達製藥集團簡介

2021 年前三季營運成果

未來營運策略

  • 企業社會責任

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

© 2021 SCP, Ltd

法說會說明程序

==> picture [98 x 91] intentionally omitted <==

提醒:會議中請將您的麥克風設定為靜音以避免聲音干擾，待發言時再將麥克風開啟

會議進行程序說明

  1. 開場

  2. 報告程序(統一於報告後接受提問)

  3. 生達製藥集團簡介、 2021 年前三季營運成果：財務長徐瑞鴻

  4. 未來營運策略、企業社會責任：總經理范滋庭

3. Q&A

請於報告結束後提問，提問時建議使用舉手功能，司儀將依序請提問者發言

2

© 2021 SCP, Ltd

免責聲明 Safe Harbor Notice

==> picture [98 x 91] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事 件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必 然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何 事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty. We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

© 2021 SCP, Ltd

==> picture [261 x 540] intentionally omitted <==

----- Start of picture text -----

© 2021 SCP, Ltd
----- End of picture text -----

簡報概要

生達製藥集團簡介

2021 年前三季營運成果

未來營運策略

企業社會責任

==> picture [98 x 91] intentionally omitted <==

4

生達集團資源整合布局

==> picture [779 x 418] intentionally omitted <==

----- Start of picture text -----

上游 製造 通路
生泰 (1982; 2005 上櫃 ) 生達 (1967; 1995 上市 )
生資 (2017)
西藥
生展 (1999; 2016 上櫃 ) 佑全 (2013 轉投資 )
盈盈 (1997)
端強 (2012 轉投資 )
保健 生展 (1999)
營養
怡發 (1999)
三友 (1994)
醫療
生展 (1999)
器材
升訊 (2000)
基因 電腦軟硬體支援
怡發 (1999)
晶片
----- End of picture text -----

==> picture [98 x 539] intentionally omitted <==

----- Start of picture text -----

Q
5
----- End of picture text -----

© 2021 SCP, Ltd

生達製藥國際認證紀錄

==> picture [698 x 46] intentionally omitted <==

----- Start of picture text -----

1998 2000 2008 2009 2010 2017 2021
----- End of picture text -----

==> picture [47 x 50] intentionally omitted <==

==> picture [32 x 42] intentionally omitted <==

1998 年台灣第一家藥廠獲 ISO 9001 認證

==> picture [56 x 35] intentionally omitted <==

==> picture [51 x 28] intentionally omitted <==

2000 年台灣第一家通過美國 FDA 查核藥廠 持續以零 483 通過美國後續性查廠

==> picture [31 x 42] intentionally omitted <==

2008 年取得日本【醫藥品外國 2018 年製劑廠及原料通過日本 製造業者認定證】 PMDA GMP 查廠

==> picture [56 x 34] intentionally omitted <==

==> picture [64 x 41] intentionally omitted <==

==> picture [54 x 38] intentionally omitted <==

2009 年通過澳洲政府 API 查廠 2010 年通過台灣 PIC/S GMP 查廠 2012 年通過台灣 GDP 藥品優良運銷 2012 年通過韓國 FDA 查廠

==> picture [54 x 40] intentionally omitted <==

==> picture [54 x 37] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

4 6
----- End of picture text -----

© 2021 SCP, Ltd

簡報概要

==> picture [98 x 91] intentionally omitted <==

生達製藥集團簡介

2021 年前三季營運成果

未來營運策略

企業社會責任

7

© 2021 SCP, Ltd

連續 54 年獲利之營運佳績

稅後淨利 現金股利 股票股利 EPS 600,000 3.50 2.99 2.93 3.00 500,000 2.50 400,000 2.09 2.15 2.09 2.09 2.11 2.03 1.95 1.88 1.90 1.77 1.81 2.00 1.73 1.61 300,000 1.47 1.35 1.50 200,000 1.80 1.00 1.20 1.50 1.25 1.20 1.60 0.50 1.00 1.20 1.00 1.50 1.50 1.60 1.50 1.50 2.50 100,000 0.50 0.70 0.30 0.30 0 0.00

==> picture [104 x 82] intentionally omitted <==

==> picture [62 x 51] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

8

© 2021 SCP, Ltd

合併綜合損益表

綜合損益表項目 2021前三季 2020 前三季 差異 年變化%
(除另予註明外，單位為NT千元)
營業收入 3,371,013 3,187,827 183,186
6%
營業毛利 1,526,457 1,413,946 112,511
8%
營業毛利率 45.28% 44.35% +0.9pct
營業費用 892,428 888,657 3,771
0%
營業利益 634,029 525,289 108,740
21%
營業外收入及支出 113,148 33,916 79,232
234%
稅前淨利 747,177 559,205 187,972
34%
本期淨利 625,114 445,656 179,458
40%
本期淨利歸屬於母公司 533,781 364,062 169,719
47%
每股盈餘(NT元) 2.99 2.04 0.95
47%

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

==> picture [64 x 64] intentionally omitted <==

9

© 2021 SCP, Ltd

==> picture [98 x 91] intentionally omitted <==

近五年每季營收比較

1 SCP, Ltd
10
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
第一季
第二季
第三季
第四季
2016
2017
2018
2019
2020
2021
單位：NT千元
Q
Q1
Q2
Q3
Q4
總計
成長%
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 1 SCP, Ltd
10
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
第一季
第二季
第三季
第四季
2016
2017
2018
2019
2020
2021
單位：NT千元
Q
Q1
Q2
Q3
Q4
總計
成長%
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 1 SCP, Ltd
10
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
第一季
第二季
第三季
第四季
2016
2017
2018
2019
2020
2021
單位：NT千元
Q
Q1
Q2
Q3
Q4
總計
成長%
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 1 SCP, Ltd
10
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
第一季
第二季
第三季
第四季
2016
2017
2018
2019
2020
2021
單位：NT千元
Q
Q1
Q2
Q3
Q4
總計
成長%
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 1 SCP, Ltd
10
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
第一季
第二季
第三季
第四季
2016
2017
2018
2019
2020
2021
單位：NT千元
Q
Q1
Q2
Q3
Q4
總計
成長%
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 1 SCP, Ltd
10
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
第一季
第二季
第三季
第四季
2016
2017
2018
2019
2020
2021
單位：NT千元
Q
Q1
Q2
Q3
Q4
總計
成長%
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 1 SCP, Ltd
10
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
第一季
第二季
第三季
第四季
2016
2017
2018
2019
2020
2021
單位：NT千元
Q
Q1
Q2
Q3
Q4
總計
成長%
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20
Q1 Q2 Q3 Q4 總計 成長%
2016 859,024 940,238 919,663 954,876 3,673,801
2017 909,933 976,177 1,056,753 905,821 3,848,684 +5%
2018 763,261 897,693 913,353 998,786 3,573,093 -7%
2019 846,177 1,010,837 1,048,886 1,031,229 3,937,129 +10%
2020 1,034,417 1,108,059 1,045,351 1,117,573 4,305,400 +9%
2021 1,101,113 1,149,060 1,120,840 3,371,013 +6%
1 SCP, Ltd

© 2021 SCP, Ltd

全球合併營收-近五年外銷比例

外銷 內銷

==> picture [642 x 251] intentionally omitted <==

----- Start of picture text -----

19.2% 80.8%
17.9% 82.1%
17.2% 82.8%
19.2% 80.8%
19.4% 80.6%
17.5% 82.5%
----- End of picture text -----

2021 前三季 2020 2019 2018 2017 2016

單位：NT千元 2021前三季 2020 2019 2018 2017 2016
外銷金額 646,019 768,863 678,464 686,077 745,705 644,528
總銷售金額 3,371,013 4,305,400 3,937,129 3,573,093 3,848,684 3,673,801

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

11
----- End of picture text -----

© 2021 SCP, Ltd

全球合併營收-外銷分布情形

全球合併營收-外銷分布情形 全球合併營收-外銷分布情形 全球合併營收-外銷分布情形 全球合併營收-外銷分布情形 全球合併營收-外銷分布情形 全球合併營收-外銷分布情形 全球合併營收-外銷分布情形 全球合併營收-外銷分布情形 全球合併營收-外銷分布情形 全球合併營收-外銷分布情形
0
50,000
100,000
150,000
200,000
250,000
300,000
中國
東南亞
亞洲其他
歐洲
日本
美洲其他
美國
非洲
其他
2021前三季
280,482
158,577
97,694
27,097
25,061
23,493
18,681
14,647
287
2020前三季
152,367
178,485
85,427
29,718
45,616
33,483
23,229
19,072
149
2021 前三季外銷實績成長0.78億(13.8%)
2021前三季
2020前三季
0 中國 東南亞 亞洲其他 歐洲 日本 美洲其他 美國 非洲 其他
2021前三季 280,482 158,577 97,694 27,097 25,061 23,493 18,681 14,647 287
2020前三季 152,367 178,485 85,427 29,718 45,616 33,483 23,229 19,072 149
SCP, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [64 x 64] intentionally omitted <==

12

© 2021 SCP, Ltd

合併資產負債表

資產負債表表項目 2021/9/30 2021/9/30 2020/9/30 2020/9/30 差異 年變化%
(除另予註明外，單位為NT千元) 金額 % 金額 %
現金及約當現金 1,325,452 18% 847,614 12% 477,838 56%
應收款項 1,073,774 14% 960,603 14% 113,171 12%
存貨 968,244 13% 909,504 13% 58,740 6%
投資 1,173,217 16% 709,160 10% 464,057 65%
不動產、廠房及設備 2,074,708 28% 2,294,229 34% (219,521) (10%)
其他 795,380 11% 1,113,357 16% (317,977) (29%)
資產總計 7,410,775 100% 6,834,467 100% 121,443 2%
流動負債 1,740,975 23% 1,615,269 24% 125,706 8%
非流動負債 526,817 7% 492,950 7% 33,867 7%
負債總計 2,267,792 31% 2,108,219 31% 159,573 8%
股東權益總計 5,142,983 69% 4,726,248 69% (38,130) (1%)
負債比率(總負債/總資產) 31% 31%
2021 SCP, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

13

© 2021 SCP, Ltd

合併現金流量表

現金流量表項目 2021前三季 2020 前三季
(除另予註明外，單位為NT千元)
期初現金 1,036,183 1,471,902
營運活動之淨現金流入 557,366 518,989
資本支出 (97,533) (268,885)
現金股利 (321,653) (268,044)
短期借款 (28,490) (39,500)
投資與其他 179,579 (566,848)
期末現金 1,325,452 847,614
自由現金流量(營運活動現金流量-資本支出) 459,833 250,104

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

==> picture [64 x 64] intentionally omitted <==

14

© 2021 SCP, Ltd

==> picture [261 x 540] intentionally omitted <==

----- Start of picture text -----

© 2021 SCP, Ltd
----- End of picture text -----

簡報概要

生達製藥集團簡介2021 年前三季營運成果

未來營運策略

企業社會責任

==> picture [98 x 91] intentionally omitted <==

15

Q

發展方向

==> picture [290 x 122] intentionally omitted <==

==> picture [96 x 123] intentionally omitted <==

From Taiwan to International From Generics to Better than Generics (BTG)

==> picture [356 x 123] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

16

© 2021 SCP, Ltd

近兩年國際重大業務

台灣 中國 日本 • • • 新冠肺炎期間產銷控 抗生素針劑持續出貨 細支氣管炎用藥、消 • 制得宜，穩定供貨 一致性評價結案 3 項， 炎止痛口服用藥持續 • 扣除一次性收入，生 5 項進行中 出貨 • 達累計營收、獲利同 自有品項：送件中 創新高

==> picture [44 x 39] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

17
----- End of picture text -----

© 2021 SCP, Ltd

- 營收成長策略 大陸

生達競爭力

  • 具美、日市場成功領證經驗

有 Fasting &Fed BE 製劑能力

中期目標

  • 自有品項送件查驗登記

增加 Profit sharing 收入

合作模式

  • 提供技術 共同持證

  • 產銷合作 利潤分享

進口自有藥證審查

一致性評價成果

  • 簽約 8 項，結案 3 項，

5 項進行中

策略

  • 進口 & 技轉雙管齊下

  • 擴大合作品項數、藥企家數

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

18
----- End of picture text -----

© 2021 SCP, Ltd

大陸醫改現況：市場趨勢變化

中國藥企 掌握原料藥 布局技術門檻高產品

原廠藥企 轉往集採以外市場

  • 原廠報價普遍較高，只 有極少數原研產品能在 集採中得標

  • 面對集採常態化，藥企 傾向自行掌握原料藥， 大幅降價，以價換量， 轉為低毛利率

  • 原廠傾向不過度降價， 即使未得標，在集採以 外的市場，仍能保持不 錯的市佔與利潤

  • 布局技術門檻高、競爭 者少的產品

國家醫保局

集採產品範圍擴大

  • 集採申報量約佔整體市 場量的 80%

  • 歷經六次集採，納入的 成份數量總共 300 個

  • 納入集採品項將逐漸擴 大到孤兒藥、短缺藥、 生物相似藥、中成藥

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

19

© 2021 SCP, Ltd

營收成長策略-日本

==> picture [76 x 72] intentionally omitted <==

合作模式

  • CDMO

  • 日本公司銷售

  • 自己持有藥證

==> picture [78 x 74] intentionally omitted <==

現況

  • 已取得 Montelukast ( 細支氣管炎用藥 )

  • 已取得 Celecoxib( 消 炎止痛用藥 )

==> picture [86 x 78] intentionally omitted <==

原料策略

  • 與原料廠商策略聯盟

  • 與生泰 /API 垂直整合

==> picture [351 x 72] intentionally omitted <==

----- Start of picture text -----

進行中
----- End of picture text -----

  • 新品項持續進行

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

© 2021 SCP, Ltd

營收成長策略-美國

==> picture [174 x 125] intentionally omitted <==

==> picture [41 x 19] intentionally omitted <==

----- Start of picture text -----

策略
----- End of picture text -----

  • 與原料藥廠商策略聯盟

  • 與生泰 /API 垂直整合

  • 全球最大藥品市場

  • 藥證審查時間冗長、成本高

  • 屬於遠程規劃目標

==> picture [41 x 19] intentionally omitted <==

----- Start of picture text -----

現況
----- End of picture text -----

  • 已出貨糖尿病及肌萎縮脊 髓側索硬化症 (ALS) 藥品

  • P4 已核准 2 項，等專利過期

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

© 2021 SCP, Ltd

– 美國 百日供應鏈報告

  • 四大關鍵供應鏈: • 半導體

  • • 大容量電池

  • • 關鍵礦物與材料

  • • 學名藥與原料藥

100 產業 天 行 政 命 令 審 目的 查

  • 審查關鍵產品對外國依賴程度

  • • 提高供應鏈多元化

  • 避免特定產品過於依賴他國(大陸、印度)

  • • 尋求亞洲、歐洲與拉美盟國協助鞏固雙方關係

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

22
----- End of picture text -----

© 2021 SCP, Ltd

生達結盟易威

==> picture [485 x 317] intentionally omitted <==

易威美國藥廠生產基地 Tulex Pharmaceutical

  • 位於紐澤西州

  • 取得美國國防部穩定訂單

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

23

© 2021 SCP, Ltd

未來策略佈局

==> picture [98 x 91] intentionally omitted <==

2022 大陸

2023

美國、日本

未來 From Taiwan to International From Generics to BTG

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

核心技術 & 專業 海外市場操作 核心技術 & 專業 海外市場操作 拓展海外業績 借力使力 借力使力

增加海外比例 增加海 外比例

==> picture [65 x 65] intentionally omitted <==

  • 加重海外業務資源 以台灣成熟尖端研發

  • 招募培訓國際人才 技術創造研發財

  • 打穩基礎

  • 快速創造營收

  • 摸索學習各國市場遊戲規則

  • 找中長期合作對象

Q

24

© 2021 SCP, Ltd

榮獲 2021 年生策會傑出生技產業金質獎

 繼 2014 年以來，再次獲得生策會傑出生技產業金質獎肯定

==> picture [489 x 307] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

25

© 2021 SCP, Ltd

‧ 榮獲 109 年衛福部 經濟部藥物科技發展獎

  • 降血壓藥品 Co-Midis Tablet 倍壓妥錠，榮獲 109 年「製造技術類」唯一金質獎最高榮譽

==> picture [246 x 371] intentionally omitted <==

  • 本產品為複方製劑，副作用小、長效型、一天 一顆，就能 24 小時平穩控制血壓

  • 歷經二年的專利審查， 2021 年 9 月取得【速放醫 藥組合物】的專利

  • 倍壓妥錠 2019 年 5 月上市，將於 2 年後，年銷售 額突破一億元

==> picture [223 x 153] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

26

© 2021 SCP, Ltd

==> picture [261 x 540] intentionally omitted <==

----- Start of picture text -----

© 2021 SCP, Ltd
----- End of picture text -----

簡報概要

生達製藥集團簡介2021 年前三季營運成果

未來營運策略

企業社會責任

==> picture [98 x 91] intentionally omitted <==

27

財團法人范道南文教基金會

基金會簡介

==> picture [184 x 137] intentionally omitted <==

  • 1987 年成立，迄今 34 年

  • 基金規模 1 億 9,600 萬元

  • 一年支出金額約 1,200 萬元

==> picture [186 x 136] intentionally omitted <==

主要業務

  • 公益性教育事務

  • 舉辦各項文教活動

  • 設置獎助學金、培育人才 贊助研究創新工作

==> picture [186 x 138] intentionally omitted <==

獲得獎項

  • 2011 年教育部評鑑優等獎

  • 2012 年台南市政府頒發捐資獎狀

  • 2013 年教育部補救教學評選全國優秀

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

28

© 2021 SCP, Ltd

==> picture [98 x 91] intentionally omitted <==

2020 年社會公益工作

==> picture [239 x 181] intentionally omitted <==

----- Start of picture text -----

獎助學金專案
大學藥學相關科系 :3 所 /4 人
高中 :7 所，共 113 人
國中 :61 所，共 807 人
國小 :237 所，共 2,760 人
補助金額 634 萬元
----- End of picture text -----

希望課輔 向日葵課輔  ~  每週一 五下午 每周三下午   22 所學校， 1,780 人 4 所學校，共 243 人 補助金額 181 萬元 補助金額 40 萬元 寒暑假營養午餐 公益活動  2020 年寒暑假營養  生達盃兒童寫生比賽  午餐供應 4,553 人次 生達盃全國桌球錦標賽 Q 補助金額 27 萬元 支出金額 25 萬元 29

==> picture [19 x 17] intentionally omitted <==

==> picture [52 x 52] intentionally omitted <==

其他公益補助

 贊助 11 家公益團體 捐助金額 56 萬元

© 2021 SCP, Ltd

樂齡健身房─達康樂活中心

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

2021 年 1~9 月

  • 使用人次累計 79,245 人次

  • 舉辦 5 場健康樂活講座，提供營養照護知識與運動體驗課程

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

30

© 2021 SCP, Ltd

公益骨密檢查與社區健康講座

==> picture [213 x 169] intentionally omitted <==

2021 年 1~9 月

  • 舉辦 3 場公益骨密檢查，累計受測人數 230 人 舉辦 2 場社區健康講座，累計 70 人參加

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

31

© 2021 SCP, Ltd

Q & A

==> picture [98 x 91] intentionally omitted <==

提問時請使用舉手功能，司儀會依序請提問者發言

==> picture [587 x 269] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

<點選麥克風開啟

32

© 2021 SCP, Ltd

More from S.C.P.C

AGM Information 2026
May 19
Interim / Quarterly Report 2026
May 14
Regulatory Filings 2026
May 14
Interim / Quarterly Report 2026
May 13
Interim / Quarterly Report 2026
May 13
Regulatory Filings 2026
May 13
Regulatory Filings 2026
May 13
Interim / Quarterly Report 2026
May 13
Regulatory Filings 2026
May 12
Earnings Release 2026
May 12
View all filings →